|
|
|
19.10.26 - 07:51
|
Poxel Reports Revenue for the Third Quarter of 2026 (Business Wire)
|
|
|
Consolidated net sales of TWYMEEG® in Japan for the third quarter of 2026 reached JPY 2.9 billion (€16.3 million1), up 29% compared to the third quarter of 2025.
Consolidated net sales of TWYMEEG® in Japan for the first nine months of 2026 reached JPY 8.1 billion (€44.5 million1), up 32% compared to the first nine months of 2025.
Net sales of TWYMEEG® exceeded the contractual threshold of JPY 5 billion in the first half of Sumitomo Pharma's fiscal year 20262: Poxel's royalty rate increases from 8% to 10% on all net sales for the fiscal year, effective retroactively.
Poxel thus generates positive net royalties for the first time (including royalties owed to Merck Serono) during Sumitomo Pharma's fiscal year 2026.
Poxel reported revenue of €1,951k in the third quarter of 2026, including a €322k retroactive adjustment to royalties from the second quarter of 2026.
Sumitomo Pharma expects net sales of TWYMEEG® to exceed JPY 10 billion in its fiscal year 20263.
Upon reaching this milestone, Poxel...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
20.05.26 - 08:03
|
Poxel Reports First Quarter 2026 Revenue and Provides a Business Update (Business Wire)
|
|
|
Consolidated net sales of TWYMEEG® in Japan for the first quarter of 2026 reached JPY 2.3 billion (€12.8 million 1), up 36% compared to the first quarter of 2025.
Poxel generated revenue of €1.277 million for the first quarter of 2026.
Consolidated net sales of TWYMEEG® in Japan for Sumitomo Pharma2 reached JPY 9.35 billion (€51 million), up 40% compared to the previous fiscal year.
During Sumitomo Pharma's fiscal year 20253, Poxel received royalties of 10% on TWYMEEG® net sales
Sumitomo Pharma expects moderate double-digit growth slightly above 10% in TWYMEEG® sales for its fiscal year 20264.
Sumitomo Pharma notably expects TWYMEEG® net sales to exceed the JPY 10 billion threshold.
Upon reaching this threshold, Poxel will receive a contractual milestone payment of JPY 1 billion (€5.5 million1), with the royalty rate increasing from 10% to 12%.
LYON, France--(BUSINESS WIRE)--Regulatory News:
Poxel (Euronext: POXEL - FR0012432516), a clinical-stage biopharmaceutical company developing innovat...
|
|
|
|
|
|
|
13.05.26 - 08:01
|
Japan OKs 1st iPS Regenerative Medicine for Insurance Coverage (Nippon)
|
|
|
Tokyo, May 13 (Jiji Press)--A Japanese health ministry council on Wednesday approved the public health insurance coverage for a regenerative medicine for Parkinson's disease produced from induced pluripotent stem, or iPS, cells, effective from May 20. With the approval by the Central Social Insurance Medical Council, which advises the health minister, Amchepry from Japan's Sumitomo Pharma C......
|
|
|
02.04.26 - 11:00
|
Sumitomo Pharma (4506.JP) Slides 9.6% on the Day as Tariff Risks Escalate (AAStocks)
|
|
|
Sumitomo Pharma (4506.JP) closed at JPY2,018.5 today (2nd), down 9.57% for the day. UK media reported that the administration of US President Donald Trump is preparing to impose a 100% tariff on certain pharmaceutical products, with the new measures aimed at forcing drugmakers to accelerate expansion of domestic production in th......
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
